Muhsen IN, Roloff GW, Faramand RG, Othman T, Valtis YK, Kopmar NE, Dekker SE, Connor M, Mercadal S, O'Connor TE, Dykes KC, Ahmed M, Jeyakumar N, Zhang A, Miller K, Sutherland KC, Guzowski C, Gupta VK, Majhail NS, Battiwalla M, Solh MM, Malik SA, Mathews J, Oliai C, Shaughnessy PJ, Mountjoy L, Lee CJ, Logan AC, Tsai SB, Leonard JT, Schwartz MS, Sasine JP, Kumaran M, Frey NV, Park JH, Koura D, Cassaday RD, Shah BD, Aldoss I, Muffly LS, Hill LC. Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement , Blood Adv: 2025

Yannis Y, Nemirovsky D, Devlin S, Roloff G, Jeyakumar N, Miller K, Zhang A, Sutherland KC, Grunwald MR, Kota V, Boccucci J, Ulrickson ML, Darobi AA, Hill LC, Muhsen IN, Sasine JP, Ahmed M, Aldoss I, Pullarkat V, Othman T, Advani AS, Reshef R, Luskin M, Chen E, Lin C, Cassaday RD, Tsai SB, Kopmar NE, O'Connor TE, Hilal T, Shah BD, Faramand R, Solh MM, Guzowski C, Bezerra E, Vasu S, Leonard JT, Dekker SE, Majhail NS, Battiwalla M, Malik S, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Oliai C, Gupta VK, Koura D, Dykes KC, Logan AC, Kumaran MV, Stock W, Schwartz M, Bachanova V, Tracy S, O'Dwyer KM, Moore JW, Lee CJ, Bobillo MSO, Frey NV, Connor MP, Jamy O, Daunov M, Ladha A, Yaghmour G, Gatell VI, Jackson C, Oluwole OO, Dholaria B, Muffly LS, Park JH. NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival , Transplant Cell Ther, 31(2): 2025,S116-S117

Faramand R, Roloff G, Aldoss I, Zhang A, Sutherland KC, Jeyakumar N, Miller K, Kota V, Boccucci J, Ulrickson ML, Darobi AA, Othman T, Advani AS, Stefan M, Lin C, Cassaday RD, Kopmar NE, Tsai SB, O'Connor TE, Hilal T, Solh MM, Guzowski C, Leonard JT, Tan V, Majhail NS, BattiwallaM, Malik S, Mathews J, Shaughnessy P, Mountjoy L, Koura D, Dykes KC, Logan AC, Schwartz M, O'Dwyer KM, Moore JW, Lee CJ, Bobillo MSO, Frey NV, Connor MP, Ladha A, Yaghmour G, Shah BD, Muffly LS. Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) , Transplant Cell Ther, 31(2): 2025,S118-S119

Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L; ROCCA Consortium. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL , J Clin Oncol, 43: 2025,558-566

Ladha A, Tan V, Yaghmour G, Zhang A, Jeyakumar N, Miller K, Muhsen IN, Logan AC, Hill LC, Cassaday RD, Luskin M, Ulrickson ML, Solh MM, Valtis Y, Battiwalla M, Bachanova V, Boccucci J, Reshef R, Tsai SB, Hoeg RT, Kota V, Othman T, Advani AS, Sasine JP, Ahmed M, Darobi AA, Pullarkat V, Stefan M, Chen EC, Lin C, Kopmar NE, Lee CJ, Bobillo MSO, O'Connor TE, Hilal T, Shah BD, Faramand R, Park JK, Guzowski C, Vasu S, Bezerra E, Majhail NS, Shaughnessy P, Malik S, Mathews J, Mountjoy L, Kumaran MV, Koura D, Dykes KC, Oliai C, Gupta VK, Stock W, Tracy S, O'Dwyer KM, Frey NV, Moore JW, Connor MP, Oluwole O, Dholaria B, Roloff G, Sutherland KC, Muffly LS, Aldoss I, Leonard JT. KMT2Ar Adversely Impacts Brexucabtagene Autoleucel (Brexu-cel) Outcome in Adults with Relapsed/Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia , Transplant Cell Ther, 31(2): 2025,S211-S212

Valtis Y, Lin C, Nemirovsky D, Devlin S, Rejeski K, Shah NS, Nair MS, Jeyakumar N, Miller K, Zhang A, Grunwald MR, Kota V, Boccucci J, Ulrickson ML, Al Darobi A, Hill LC, Muhsen IN, Sasine JP, Ahmed M, Aldoss I, Othman T, Advani AS, Reshef R, Luskin M, Chen E, Cassaday RD, Kopmar NE, Tsai SB, O'Connor TE, Hilal T, Shah BD, Faramand R, Solh MM, Guzowski C, Vasu S, Bezerra E, Leonard JT, Dekker SE, Majhail NS, Battiwalla M, Malik S, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Oliai C, Gupta VK, Koura D, Dykes KC, Logan AC, Kumaran MV, Stock W, Schwartz M, Bachanova V, Tracy S, O'Dwyer KM, Moore JW, Lee CJ, Odstrcil Bobillo MS, Frey NV, Connor MP, Jamy O, Daunov M, Ladha A, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole OO, Dholaria B, Sutherland KC, Roloff G, Muffly LS, Park JH. CAR and ALL Hematotox Scores Predict Toxicity and Outcomes Among Recipients of Brexucabtagene Autoleucel for R/R ALL in the Real World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) Consortium , Transplant Cell Ther, 31(2): 2025,S8-S10

Othman T, Pullarkat V, Roloff G, Jeyakumar N, Miller K, Zhang A, Sutherland KC, Hill LC, Muhsen IN, Sasine J, Ahmed M, Advani AS, Stefan M, Lin C, Cassaday RD, Kopmar NE, Tsai SB, O'Connor TE, Hilal T, Shah BD, Faramand R, Solh MM, Guzowski C, Leonard JT, Tan V, Majhail NS, Battiwalla M, Malik S, Mathews J, Shaughnessy P, Mountjoy L, Koura D, Dykes KC, Logan AC, Schwartz M, O'Dwyer KM, Moore JW, Lee CJ, Odstrcil Bobillo MS, Frey NV, Connor MP, Ladha A, Yaghmour G, Muffly LS, Aldoss I. Tyrosine Kinase Inhibitor (TKI) Maintenance Improves Remission Durability in Philadelphia-Chromosome Acute Lymphoblastic Leukemia (Ph+ ALL) Following Brexucabtagene Autoleucel (Brexu-cel) , Transplant Cell Ther, 31(2): 2025,S122-S123

Aldoss I, Roloff GW, Faramand R, Kopmar NE, Lin C, Advani AS, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Zhang A, Miller K, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Dholaria B, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Logan AC, Ladha A, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor M, O'Dwyer KM, Hill LC, Tsai SB, Sasine J, Solh MM, Lee CJ, Kota VK, Koura D, Veeraputhiran M, Blunk B, Oliai C, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Bishop MR, Stock W, Cassaday RD, Pullarkat V, Shah BD, Muffly LS. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL , Blood Adv, 8: 2024,6139-6147

Muhsen I, Advani AS, Roloff GW, Jeyakumar N, Miller K, Zhang A, Sutherland KC, Grunwald MR, Kota VK, Boccucci J, Ulrickson M, Sasine J, Aldoss I, Othman T, Vasu S, Reshef R, Luskin MR, Chen EC, Lin C, Langston A, Cassaday RD, Kopmar NE, Tsai SB, O'Connor TE, Hilal T, Faramand R, Park JH, Valtis YK, Solh MM, Bezerra E, Leonard JT, Dekker SE, Majhail N, Battiwalla M, Malik SA, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Oliai CH, Gupta V, Koura D, Dykes KC, Logan AC, Kumaran MV, Stock W, Schwartz M, Bachanova V, Tracy S, O'Dwyer KM, Moore J, Lee CJ, Odstrcil Bobillo MS, Frey N, Connor MP, Jamy O, Daunov M, Ladha A, Yaghmour G, Jackson C, Irrizary Gatell V, Oluwole OO, Dholaria B, Pullarkat V, Merchant A, Shah BD, Muffly L, Hill L. Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above , Blood, 144(Supplement 1): 2024,523

Valtis YK, Nemirovsky D, Devlin SM, Roloff GW, Aldoss I, Jeyakumar N, Miller K, Zhang A, Sutherland KC, Advani AS, Luskin MR, Chen EC, Jamy O, Grunwald MR, Muhsen I, Kopmar NE, Dholaria B, Dekker SE, Leonard JT, Yaghmour G, Tsai SB, Stock W, Moore J, O'Dwyer KM, Logan AC, Connor MP, Frey N, Bezerra E, Vasu S, Dykes KC, Battiwalla M, Lin C, Ulrickson M, Reshef R, Cassaday RD, Hill LC, Lee CJ, Kota VK, Boccucci J, Sasine J, Merchant A, Pullarkat V, Langston A, Hilal T, Faramand R, Solh MM, Othman T, O'Connor TE, Majhail N, Malik S, Mountjoy L, Hoeg RT, Oliai CH, Gupta V, Koura D, Kumaran MV, Schwartz M, Bachanova V, Tracy SI, Odstrcil Bobillo M, Ladha A, Jackson C, Irrizary Gatell V, Oluwole OO, Daunov M, Mathews J, Shaughnessy P, Shah BD, Muffly L, Park JH. NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival , Blood, 144(Supplement 1): 2024,4200